Skip to main content
PMC home page
Experimental & Molecular Medicine logoLink to Experimental & Molecular Medicine
. 2013 Jan 18;45(1):e5. doi: 10.1038/emm.2013.10

Acetyl salicylic acid inhibits Th17 airway inflammation via blockade of IL-6 and IL-17 positive feedback

Hyung-Geun Moon 1, Chil Sung Kang 1, Jun-Pyo Choi 1, Dong Sic Choi 1, Hyun Il Choi 1, Yong Wook Choi 1, Seong Gyu Jeon 1, Joo-Yeon Yoo 1, Myoung Ho Jang 2, Yong Song Gho 1, Yoon-Keun Kim 1,*
PMCID: PMC3584657  PMID: 23306703

Abstract

T-helper (Th)17 cell responses are important for the development of neutrophilic inflammatory disease. Recently, we found that acetyl salicylic acid (ASA) inhibited Th17 airway inflammation in an asthma mouse model induced by sensitization with lipopolysaccharide (LPS)-containing allergens. To investigate the mechanism(s) of the inhibitory effect of ASA on the development of Th17 airway inflammation, a neutrophilic asthma mouse model was generated by intranasal sensitization with LPS plus ovalbumin (OVA) and then challenged with OVA alone. Immunologic parameters and airway inflammation were evaluated 6 and 48 h after the last OVA challenge. ASA inhibited the production of interleukin (IL)-17 from lung T cells as well as in vitro Th17 polarization induced by IL-6. Additionally, ASA, but not salicylic acid, suppressed Th17 airway inflammation, which was associated with decreased expression of acetyl-STAT3 (downstream signaling of IL-6) in the lung. Moreover, the production of IL-6 from inflammatory cells, induced by IL-17, was abolished by treatment with ASA, whereas that induced by LPS was not. Altogether, ASA, likely via its acetyl moiety, inhibits Th17 airway inflammation by blockade of IL-6 and IL-17 positive feedback.

Keywords: Acetyl salicylic acid, IL-6, IL-17A, STAT3, Th17

Introduction

Asthma is a complex syndrome with many clinical phenotypes; its major characteristics include a variable degree of airflow obstruction, airway hyperresponsiveness, and eosinophilic or non-eosinophilic inflammation.1 Severe persistent and/or difficult-to-control asthma may be associated with neutrophilic airway inflammation, whereas mild and moderate asthma may be related to eosinophilic airway inflammation.1, 2 In terms of asthma immunopathogenesis, airway inflammation in asthma patients can be categorized according to the involvement of particular CD4+ T cell subsets, including T-helper (Th)1, Th2 and Th17.3

In the past several years, Th17 cell response has been highlighted as a key player in neutrophilic airway inflammation, and overexpression of interleukin (IL)-17 in airway epithelial cells has been related to neutrophilic airway inflammation.4 Additionally, airway exposure to lipopolysaccharide (LPS)-containing allergens induces IL-17-dependent neutrophilic airway inflammation.5 IL-6 is a key inducer of Th17 cell responses in the lung. In terms of Th17 polarization, signal transducer and activator of T cells (STAT)3 and retinoid-related orphan receptor (ROR)γt are important transcription factors.6, 7 Induction of RORγt is dependent on STAT3 signaling, which is preferentially activated by IL-6.8

Acetyl salicylic acid (ASA), or aspirin, has been prescribed for the treatment of several inflammatory conditions for several decades. ASA inhibits cyclooxygenase (COX) enzymes, which are related to the production of pro-inflammatory arachidonic acid metabolites.9 However, several mechanisms of the anti-inflammatory effects of ASA, other than COX inhibition, have been proposed: ASA inhibits the activity of IκB kinase-β, thereby preventing activation of nuclear factor-κB, which is involved in the pathogenesis of inflammation;10 ASA triggers anti-inflammatory 15-epi-lipoxin A11 and induction of apoptosis of inflammatory cells via the mitogen-activated protein kinase pathway;12 and ASA inhibits the accumulation of inflammatory cells in an adenosine-dependent manner.13

Previously, we demonstrated that ASA inhibited Th17 inflammation, but enhanced Th2 inflammation in the lung.14 In the present study, we aimed to determine the mechanism(s) of the inhibitory effect of ASA on the development of allergen-induced Th17 airway inflammation.

Materials and methods

Mice

Wild-type (WT) and interferon (IFN)-γ−/− C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). IL-17A−/− and OT-II C57BL/6 mice were kindly donated by Y-C Sung (Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea). These mice were bred in an animal laboratory at POSTECH. Age- and sex-matched mice were used for control animal experiments. Animal study protocols were approved by the Institutional Animal Care and Use Committee of POSTECH.

Chemicals, recombinant proteins and drugs

LPS and ovalbumin (OVA) was purchased from Calbiochem (Darmstadt, Germany) and Sigma-Aldrich (St Louis, MO, USA), respectively. Recombinant IL-6 (rIL-6), rIL-12 and rTGF-β1 were purchased from R&D Systems (Minneapolis, MN, USA). ASA (aspirin-lysine) was purchased from Ilyang Pharmaceutical Co. (Yongin-si, Gyeonggi-do, Republic of Korea), and salicylic acid (SA) and celecoxib (a COX2 inhibitor) were purchased from Sigma-Aldrich.

Protocol for the generation of a neutrophilic asthma mouse model

As an allergen, OVA was used after LPS depletion from the OVA antigen stock, as described previously.15 A neutrophilic asthma mouse model was generated as described previously.5 Briefly, 6-week-old mice were sensitized intranasally with OVA (75 μg) and LPS (10 μg) on days 0, 1, 2 and 7 and then challenged intranasally with OVA (50 μg) alone on days 14, 15, 21 and 22. As a negative control, mice were sensitized with OVA (75 μg) alone and then challenged with phosphate-buffered saline (PBS; 30 μl). Drugs (ASA, SA and celecoxib) were administered intraperitoneally on days 14, 15, 21 and once on day 22 right away after the OVA challenge.

Cellularity in bronchoalveolar lavage (BAL) fluids

BAL fluids were obtained as described previously.15 Briefly, mice were anesthetized with ketamine, and the trachea was isolated by blunt dissection. A small-caliber tube was inserted and secured in the airway. Two successive volumes of 0.75 ml PBS were instilled and gently aspirated, and these two volumes were pooled. Each BAL sample was centrifuged, and the supernatants were stored at −70 °C until use. The total number of inflammatory cells was counted after re-suspension of the cell pellets with 100 μl PBS. After Diff-Quick staining (Dade Behring, Inc., Newark, DE, USA) of the BAL cells in a cytospin preparation, the types of inflammatory cells were determined by counting 300 cells, which were classified as macrophages, lymphocytes, neutrophils or eosinophils, and the percentages of each cell type were calculated.

Intracellular staining of T cells in lung tissues and lung-draining lymph nodes (LN)

Cells were isolated from lung tissues and regional LN (4 × 106 ml−1) and were incubated in 48-well plates coated with anti-CD3 plus anti-CD28 antibodies (Abs; 1 μg ml−1 each; eBioscience, San Diego, CA, USA) at 37 °C for 6 h and then re-stimulated with Brefeldin A (10 μg ml−1) for 2 h. Cells were stained with surface protein-specific Abs (allophycocyanin-conjugated anti-CD3, fluorescein (FITC)-conjugated anti-CD4 and phycoerythrin-Cy5-conjugated anti-CD8; BD Biosciences, San Jose, CA, USA) for 30 min at 4 °C and then fixed for 10 min in 4% paraformaldehyde at room temperature. Cells were incubated with Abs to candidate cytokines (anti-IL-17-PE; BD Biosciences) for 30 min at room temperature and analyzed on a FACSCalibur flow cytometer (BD Biosciences) and using CellQuest software (BD Biosciences). The number of cells in the lung was determined by multiplying the total number of lung cells by the percentage of CD4+IL-17A+ T cells.

Cytokine production from T cells after non-specific and allergen-specific stimulation

Single-cell suspensions from spleens, lung tissues or lung-draining LN were prepared. Cells were incubated with non-specific stimuli (anti-CD3 plus anti-CD28 antibodies (Abs)) for 12 h and with OVA (100 μg ml−1) for 72 h. Cytokine levels in supernatants were measured.

Enzyme-linked immunosorbent assay (ELISA)

IFN-γ, IL-17, IL-6, tumor necrosis factor-α and monocyte chemotactic protein-1 levels were quantified via ELISA, following the manufacturer's instructions (R&D Systems).

Preparation of bone marrow dendritic cells (BMDCs)

BMDCs were prepared by following the methods of Lutz et al.16 In brief, bone marrow cells were prepared and cultured in Petri dishes for 3 days with granulocyte/macrophage-colony stimulating factor (GM-CSF; 20 ng ml−1). Three days later, 10 ml culture media was added. On days 6 and 8, culture supernatants were collected and then centrifuged. Cells were re-suspended in culture media containing GM-CSF (20 ng ml−1). On day 10, cells were collected by centrifugation and then re-suspended in culture media with GM-CSF (5 ng ml−1).

Antigen uptake by immune cells

Antigen uptake analysis was conducted in Raw 264.7 cells (macrophage cell lines) and BMDCs using OVA-FITC (Invitrogen, Life Technologies, Grand Island, NY, USA) and the FACSCalibur flow cytometer.

In vitro differentiation

Splenocytes from WT, OT-II and IFN-γ−/− mice were prepared as single-cell suspensions. CD4+ T cells, OT-II CD4+ T cells and CD11c+ DCs were isolated by autoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany) from the splenocytes of WT and IFN-γ−/− mice. To differentiate Th1 and Th17 subtypes, cells were cultured with mouse rIL-12 (10 ng ml−1), mouse IL-6 (20 ng ml−1) and human TGF-β1 (10 ng ml−1) in an anti-CD3 (1 μg ml−1) antibody-coated culture plate for 3 days. All Abs were purchased from R&D Systems. IL-17A production was assayed by ELISA, and the presence of CD4+IL-17A+ T cells was confirmed using the FACSCalibur flow cytometer.

Western blotting and immunoprecipitation assay

Lung tissues were homogenized with ice-cold RIPA buffer (50 mℳ Tris–HCl, pH 7.5, 1% NP-40, 0.25% Na-deoxycholate, 100 mℳ NaCl, 1 mℳ EDTA, protease inhibitor). Protein concentrations were determined by the DC protein assay kit (Bio-Rad, Hercules, CA, USA) using bovine serum albumin as a standard. The lung lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. The blocked membrane was then incubated with the antibodies indicated, including those against actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), RORγt (BioLegend, San Diego, CA, USA), STAT3 (Cell Signaling Technology), phospho-STAT3 (pSTAT3) (Cell Signaling Technology), acetyl lysine (Abcam, Cambridge, UK) and streptavidin-POD (Roche, Mannheim, Germany). Immunoreactive bands were visualized using a chemiluminescent substrate. For immunoprecipitation assays, lung lysates were incubated with STAT3 antibody-immobilized beads (Cell Signaling Technology) overnight, washed with ice-cold RIPA buffer and eluted in 2 × SDS loading dye.

Statistical analysis

Significant differences between the treatments were assessed using Student's t-test, analysis of variance or Wilcoxon's rank-sum test. For multiple comparisons, analysis of variance was first used, and if significant differences were found, individual t-tests or Wilcoxon's rank-sum tests for pairs of groups were then performed.

Results

Effects of ASA on the development of Th17 airway inflammation in IFN-γ-deficient mice

Previous experimental evidence indicated that ASA treatment during allergen challenge inhibited Th17 airway inflammation, but not Th1 inflammation, in a neutrophilic asthma model induced by airway sensitization with LPS-containing allergens.14 To further delineate the effect of ASA on the development of Th17 airway inflammation, the neutrophilic asthma model was developed in IFN-γ−/− and IL17A−/− mice with and without treatment of ASA (18 mg kg−1). In the present study, BAL cellularity analysis 24 h after the last OVA challenge showed that lung infiltration of inflammatory cells induced by sensitization with LPS-containing OVA was significantly lower in IFN-γ−/− mice treated with ASA than in IFN-γ−/− mice treated with a sham control, whereas this phenotype was similar in IL-17A−/− and WT mice after ASA treatment compared to sham treatment (Figure 1a). Based on the finding that the inhibitory effect of ASA on the development of airway inflammation was prominent in IFN-γ−/− mice, we further analyzed the therapeutic effects of ASA in IFN-γ−/− mice. BAL cellularity analysis 48 h after the last OVA challenge showed that lung infiltration of macrophages, lymphocytes, neutrophils and eosinophils induced by sensitization with LPS-containing OVA was significantly inhibited by ASA treatment compared to sham treatment (Figure 1b). The present study showed that IL-17A levels in the culture supernatants of lung cells after stimulation with anti-CD3 plus anti-CD28 antibodies and also with OVA were enhanced in OVA-challenged mice compared to PBS-challenged mice; this increased production was significantly inhibited by ASA treatment (Figure 1c). In addition, the number of Th17 cells in the lung tissue, enhanced by OVA challenge, was significantly decreased by ASA treatment, but not by sham treatment (Figure 1d). Collectively, these findings suggested that ASA suppressed lung infiltration of Th17 cells and Th17 inflammation, especially in an IFN-γ-deficient state.

Figure 1.

Figure 1

Open in a new tab

Acetylsalicylic acid (ASA) inhibits T-helper 17 inflammation in the lung. Wild-type (WT), interleukin (IL)-17A−/− and interferon (IFN)-γ−/− mice were sensitized intranasally with lipopolysaccharide (LPS) (10 μg) plus ovalbumin (OVA) (75 μg) and then challenged with OVA (50 μg) alone. Evaluation (n=5 per group) was performed 48 h after the last OVA challenge. (a) Infiltrated bronchoalveolar lavage (BAL) cells by OVA provocation with or without ASA administration in WT, IL-17A−/− and IFN-γ−/− mice. (b) BAL cellularity in IFN-γ−/− mice. (c) Level of IL-17 A production after re-stimulation by anti-CD3 plus anti-CD28 or OVA in IFN-γ−/− mice. (d) Flow cytometry analysis of CD4+IL-17A+ T cells, and the number of CD4+IL-17A+ T cells in the lung tissue of IFN-γ−/− mice. PBS, phosphate-buffered saline. *P<0.05.

Effects of ASA on the development of IL-6-induced Th17 polarization

IL-6, along with TGF-β1, is a well-known key mediator of Th17 polarization.8 We aimed to evaluate the effect of ASA on Th17 polarization of naive T cells. To test this, naive splenocytes were isolated from WT and IFN-γ−/− mice, and rIL-6 (20 ng ml−1) and rTGF-β1 (10 ng ml−1) were added to the splenocytes followed by incubation in an anti-CD3 (1 μg)-coated plate for 3 days.17 Anti-CD3-stimulated IL-17A production from splenocytes, enhanced by IL-6 and TGF-β1, was diminished by ASA treatment in a dose-dependent manner in both WT and IFN-γ−/− mice (Figure 2a). In terms of the effect of ASA on Th1 polarization, the present study showed that the production of IFN-γ from WT splenocytes was enhanced by rIL-12 (10 ng ml−1), but was not affected by ASA treatment (Figure 2b). Next, we isolated CD4+ T cells from WT splenocytes and then cultured the cells with rIL-6 (20 ng ml−1) and rTGF-β1 (10 ng ml−1) with or without treatment with ASA (1000 nM) in anti-CD3 antibody-coated plates for 3 days. Data suggested that IL-17A production from CD4+ T cells, induced by IL-6 and TGF-β1, was significantly inhibited by ASA treatment (Figure 2c). Furthermore, CD4+ T cells were isolated from OT-II splenocytes and CD11c+ DCs were isolated from IFN-γ−/− splenocytes, and then CD4+ T cells, CD11c+ DCs and SIINFEKL (an OT-II-specific peptide; 10 μg) were co-cultured in Th17-driving conditions for 3 days. IL-17A production from OT-II CD4+ T cells was significantly enhanced by Th17-polarizing conditions, and this enhanced production was significantly inhibited by ASA treatment (Figure 2d). In addition, the number of Th17 cells was found to be enhanced by TGF-β1 and IL-6; this increase was abolished by ASA treatment (Figure 2e). Collectively, these data suggest that ASA suppressed Th17 polarization induced by IL-6 and TGF-β1, but not Th1 polarization induced by IL-12.

Figure 2.

Figure 2

Open in a new tab

Acetylsalicylic acid (ASA) inhibits T-helper (Th)17 polarization induced by interleukin (IL)-6 and transforming growth factor (TGF)-β1. (a, b) Naive splenocytes were isolated from wild-type (WT) and interferon (IFN)-γ−/− mice and then polarized with IL-6 and TGF-β1 for 3 days. The level of IL-17A produced by WT and IFN-γ−/− splenocytes is shown after stimulation with recombinant IL-6 (rIL-6) (20 ng ml−1) plus rTGF-β1 (10 ng ml−1), anti-CD3 (1 μg) or different doses of ASA, and the level of IFN-γ by rIL-12 (10 ng ml−1). (c–e) CD4+ T cells and CD11c+ dendritic cells (DCs) were isolated using autoMACS. (c) The level of IL-17A produced by WT CD4+ T cells is shown after stimulation with anti-CD3 (10 μg ml−1), rIL-6 (20 ng ml−1) plus rTGF-β1 (10 ng ml−1) or ASA (1000 nℳ) for 3 days. (d) The level of IL-17A produced from co-cultured OT-II CD4+ T cells, CD11c+ DCs and SIINFEKL is shown after culture in Th17-differentiating conditions for 3 days. (e) Flow cytometric analysis of the cells in panel (c). *P<0.05.

Effects of the acetyl moiety of ASA on the development of Th17 cell responses

The first known mechanism of action of ASA was the inhibition of COX1 and COX2 via acetylation of these enzymes.9 To investigate the effect of COX2 inhibition by the acetyl moiety of ASA on the development of Th17 airway inflammation, the therapeutic effect of SA, with no acetyl moiety, and of celecoxib (a selective COX2 inhibitor) was evaluated in the neutrophilic asthma model. SA (15 mg kg−1) and celecoxib (10 mg kg−1) were administered intraperitoneally during OVA challenge in IFN-γ−/− mice. BAL cellularity analysis showed that lung infiltration of inflammatory cells, especially neutrophils, was markedly inhibited by ASA, partially inhibited by celecoxib, but not affected by SA treatment (Figure 3a). Similarly, anti-CD3/CD28-induced IL-17A production from T cells in lung-draining LN was found to be significantly reduced by ASA or celecoxib treatment, but not by SA (Figure 3b). These data suggest that the acetyl moiety of ASA was important in the inhibition of Th17 airway inflammation, possibly via COX2 inhibition.

Figure 3.

Figure 3

Open in a new tab

Th17 inflammation in the lung is not inhibited by salicylic acid (SA) treatment. Acetylsalicylic acid (ASA), SA and celecoxib (Coxib) were administered intraperitoneally during ovalbumin (OVA) challenge in the neutrophilic asthma model. (a) Bronchoalveolar lavage (BAL) cellularity in interferon (IFN)-γ−/− mice. (b) Level of interleukin (IL)-17A production from lung-draining lymph node (LN) cells, which were stimulated with anti-CD3 plus anti-CD28 in IFN-γ−/− mice. (c) Western blotting of signal tranducer and activator of transcription 3 (STAT3), pSTAT3, acetyl-STAT3 and retinoid-related orphan receptor (ROR)γt levels in lung tissue. PBS, phosphate-buffered saline. *P<0.05.

We also evaluated the effects of these drugs on the expression of RORγt, STAT3, pSTAT3 and acetyl-STAT3 in lung tissues from IFN-γ−/− mice after OVA challenge, as shown in Figure 3c. This study showed that ASA inhibited the expression of acetyl-STAT3, but not of pSTAT3 or RORγt. In addition, celecoxib was found to diminish the expression of acetyl-STAT3 and also of pSTAT3 and RORγt. In contrast, the expression of acetyl-STAT3, pSTAT3 and RORγt was not affected by SA treatment, although STAT3 expression was enhanced. To summarize, these findings suggest that the acetyl moiety of ASA inhibited the Th17 cell response possibly via downregulation of acetyl-STAT3 expression.

Effect of ASA on the in vitro production of IL-6 induced by LPS or IL-17

Among the innate immune cells, DCs orchestrate the fate of naive CD4+ T cells into Th1, Th2, Th17 or Treg cells.18 To investigate the effect of ASA on the development of LPS-induced innate immune responses from antigen-presenting cells, BMDCs were prepared following the method of Lutz et al.16 and stimulated with LPS (10 ng ml−1). First, we evaluated the effect of ASA on in vitro antigen uptake by BMDCs and used OVA-FITC as an antigen. The current study showed that LPS did not enhance the uptake of OVA by BMDCs; this phenotype was also unaffected by ASA treatment, irrespective of ASA dose (Figure 4A). Next, the effect of ASA on the expression of co-stimulatory molecules on BMDCs was evaluated. This study showed that the expression of co-stimulatory molecules, such as MHCII, CD11b and CD80 enhanced by LPS, was not inhibited by ASA treatment, irrespective of ASA dose (Figure 4b). In terms of the production of IL-6 (a Th17-polarizing cytokine), data indicated that IL-6 production from BMDCs was enhanced by LPS, but not inhibited by ASA treatment, irrespective of its dose (Figure 4c).

Figure 4.

Figure 4

Open in a new tab

In vitro production of interleukin (IL)-6 induced by IL-17A, but not by lipopolysaccharide (LPS), is inhibited by acetylsalicylic acid (ASA) treatment. (a) Antigen (ovalbumin (OVA)) uptake by bone marrow dendritic cells (BMDCs) after stimulation with LPS and different doses of ASA. (b) Flow cytometric analysis of BMDC maturation. BMDCs were stimulated with LPS (10 ng ml−1) and ASA and then stained with anti-CD11c, anti-MHCII, anti-CD11b, and anti-CD80 antibodies. (c) Level of IL-6 in the culture supernatants of BMDCs stimulated with LPS (10 ng ml−1) and ASA. (d) Level of IL-6 in the culture supernatants of Raw 264.7 cells activated by LPS (10 ng ml−1), rIL-17A (50 ng ml−1) or ASA. FITC, fluorescein. *P<0.05. MFI, mean fluorescent intensity.

IL-17A secreted from CD4+ T cells induces the production of IL-6 from inflammatory cells, such as macrophages and neutrophils,19 and rIL-17 induces the production of IL-6 in Th17-derived autoimmune hepatitis.20 To elucidate the effect of ASA on the production of IL-6 induced by IL-17, Raw 264.7 cells were stimulated with LPS (10 ng ml−1) and rIL-17A (50 ng ml−1). Data suggested that IL-6 production was enhanced to a greater degree by LPS plus rIL-17A compared to LPS alone; interestingly, the production of IL-6 enhanced by rIL-17A, but not by LPS, was inhibited by ASA treatment (Figure 4d). These data suggest that ASA suppressed the production of IL-6 from inflammatory cells, especially macrophages, induced by Th17 cells.

Effect of ASA on the in vivo production of IL-6 induced by LPS or IL-17

Based on the above data, we evaluated the effect of ASA on the development of in vivo innate immune responses induced by LPS. To test this, LPS (10 μg) was administered intranasally into the mouse airway for 3 days with and without treatment of ASA (18 mg kg−1) once a day, and then the mice were evaluated 24 h later. BAL cellularity analysis showed that lung infiltration of inflammatory cells was enhanced by LPS, but not affected by ASA treatment (Figure 5a). Additionally, IL-6 production, enhanced by LPS, was not inhibited by ASA treatment (Figure 5b). Moreover, the present study showed that co-stimulatory molecule (CD11b, CD80 and CD86) expression by lung DCs, enhanced by LPS, was not inhibited by ASA treatment (Figure 5c). Taken together, these data suggest that ASA did not modulate in vivo innate immune responses induced by airway exposure to LPS.

Figure 5.

Figure 5

Open in a new tab

In vivo production of interleukin (IL)-6 induced by IL-17A, but not by lipopolysaccharide (LPS), is inhibited by acetylsalicylic acid (ASA) treatment. (a–c) LPS was administered into wild-type mouse airways for 3 days with and without intraperitoneal treatment with ASA. (a) Bronchoalveolar lavage (BAL) cellularity. (b) BAL IL-6 levels. (c) Flow cytometric analysis of lung dendritic cell (DC) maturation. Lung DCs were stained with anti-CD11c, anti-CD11b, anti-CD80 and anti-CD86 Abs. (d, e) LPS and rIL-17 were administered into WT mouse airways for 3 days with and without intraperitoneal treatment with ASA. (d) BAL cellularity. (e) IL-6 levels in BAL fluid. PBS, phosphate-buffered saline. *P<0.05.

Finally, we evaluated the effect of ASA on the in vivo development of airway inflammation and IL-6 production induced by airway exposure to rIL-17A. To test this, LPS (10 μg) was administered intranasally into the mouse airway with or without rIL-17A (2.5 μg kg−1). BAL cellularity analysis showed that lung infiltration of neutrophils was significantly increased by LPS plus rIL-17A exposure rather than by LPS exposure alone; interestingly, neutrophil infiltration induced by rIL-17A, but not by LPS, was completely inhibited by ASA treatment (Figure 5d). Similarly, the current study showed that IL-6 production induced by rIL-17A, but not by LPS, was inhibited by ASA treatment (Figure 5e). Collectively, these data suggest that ASA inhibited Th17 airway inflammation, partly via downregulation of IL-6 production in macrophages induced by Th17 cells.

Discussion

Since it was highlighted in the literature several years ago, various diseases have been explained by Th17 inflammation, such as multiple sclerosis, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, asthma and even certain cancers.19 Our previous data demonstrated that ASA inhibited Th17 airway inflammation.14 In the present study, we aimed to elucidate the mechanism(s) of action of the inhibitory effect of ASA on the development of allergen-induced Th17 inflammation in the lung. The present study showed that ASA inhibited Th17 airway inflammation via suppression of IL-6 and IL-17 positive feedback, that is, IL-6-induced Th17 polarization and Th17 cell-induced IL-6 production.

In humans, IL-1β, IL-6 and IL-23 are the key cytokines that induce Th17 polarization, whereas IL-1β, IL-6 and TGF-β1 are crucial in mice.19, 21 In addition, IL-21, IL-22 and IL-23 are important for maintenance of Th17 cell responses in both humans and mice.8, 21 In the driving conditions of Th17 polarization in mouse airways, IL-6 leads to induction of a Th17 cell response.8 A previous study also indicated that airway exposure to LPS-containing allergens induced Th17 cell responses via the VEGF–IL-6 pathway.5 In the present study, ASA was found to inhibit Th17 polarization induced by IL-6, although IL-6 production induced by LPS was not altered by ASA treatment. Collectively, these data indicate that ASA inhibits Th17 polarization induced by IL-6.

STAT3 is known to be a primary player in the pathway downstream of IL-6.22 pSTAT3 is the active form of the molecule, which induces pro-inflammatory gene expression.23 Thus, pSTAT3 has been considered as a marker of Th17 development. On the other hand, the mechanisms of action of RORα, β and γ, in addition to their physiological functions and potential role in several pathologies, were elucidated within the last few years.24 Among ROR family members, RORγt is a STAT3 downstream signaling molecule and essential for lineage specification of naive CD4+ T cells into Th17 cells.6, 7, 24 However, the present study showed that ASA did not affect the expression of pSTAT3 or RORγt. These findings suggest that ASA inhibited IL-6-induced Th17 polarization via pathways other than pSTAT3 and RORγt.

The acetyl moiety of ASA is known to inhibit the functions of COX enzymes via acetylation.9 The present study aimed to evaluate the effect of the acetyl moiety of ASA on the development of Th17 airway inflammation by comparison with SA. Data suggested that ASA inhibited IL-6-induced Th17 cell responses, whereas SA did not. Recently, acetyl-STAT3 has been suggested to also be an active form of STAT3.25 Acetylation of STAT3 at Lys685 can be induced by IL-6 via PI3K/Akt activation.26 Interestingly, the current study showed that the expression of acetyl-STAT3 was diminished by ASA treatment, but not by SA. To sum up, these data suggest that the acetyl moiety of ASA inhibited IL-6-induced Th17 cell responses, possibly via blockade of acetyl-STAT3 expression.

IL-6 is also a downstream mediator of Th17 cell responses.14 IL-17A interacts with IL-17RA or IL-17RC, which transmits signals to TRAF-6-dependent or -independent pathways.27, 28, 29 The present study showed that the production of IL-6, which was enhanced by IL-17A, was suppressed by ASA treatment. Taking into consideration the fact that ASA inhibited IL-6-induced Th17 polarization, the above data indicate that ASA inhibited the development of Th17 airway inflammation via blockade of IL-6 and IL-17A positive feedback.

In summary, the present study indicates that ASA selectively suppresses Th17 airway inflammation, but not Th1-mediated inflammation, in a neutrophilic asthma model. Furthermore, ASA inhibits IL-6-induced Th17 polarization, which is related to the downregulation of acetyl-STAT3 expression. Additionally, ASA blocks IL-17A-induced inflammation and IL-6 production. Thus, ASA can be used to treat Th17-dominant neutrophilic asthma.

Acknowledgments

We thank Jee-In Lim for providing secretarial assistance and members of the POSTECH animal facility for their help with the animal experiments. This study was supported by the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (20120008992).

The authors declare no conflict of interest.

References

  1. Busse WW, Lemanske RFJ. Asthma. N Engl J Med. 2001;344:350–362. doi: 10.1056/NEJM200102013440507. [DOI] [PubMed] [Google Scholar]
  2. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–178. doi: 10.1183/09031936.00138707. [DOI] [PubMed] [Google Scholar]
  3. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology. 2009;127:450–458. doi: 10.1111/j.1365-2567.2009.03114.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–1141. doi: 10.1038/ni1261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kim YS, Hong SW, Choi JP, Shin TS, Moon HG, Choi EJ, et al. Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type 1 and type 17 T helper cells in the airways. J Immunol. 2009;183:5113–5120. doi: 10.4049/jimmunol.0901566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–11233. doi: 10.1016/j.cell.2006.07.035. [DOI] [PubMed] [Google Scholar]
  7. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011;12:247–254. doi: 10.1038/ni.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517. doi: 10.1146/annurev.immunol.021908.132710. [DOI] [PubMed] [Google Scholar]
  9. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971;231:232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  10. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activityof IkB kinase-β. Nature. 1998;396:77–80. doi: 10.1038/23948. [DOI] [PubMed] [Google Scholar]
  11. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA. 1995;92:9475–9479. doi: 10.1073/pnas.92.21.9475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA. 1997;94:2869–2873. doi: 10.1073/pnas.94.7.2869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci USA. 1999;96:6377–6381. doi: 10.1073/pnas.96.11.6377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moon HG, Tae YM, Kim YS, Jeon SG, Oh SY, Gho YS, et al. Conversion of Th17-type into Th2-type inflammation by acetyl salicylic acid via the adenosine and uric acid pathway in the lung. Allergy. 2010;65:1093–1103. doi: 10.1111/j.1398-9995.2010.02352.x. [DOI] [PubMed] [Google Scholar]
  15. Kim YK, Oh SY, Jeon SG, Park HW, Lee SY, Chun EY, et al. Airway exposure levels of lipopolysaccharide determine type 1 versus type 2 experimental asthma. J Immunol. 2007;178:5375–5382. doi: 10.4049/jimmunol.178.8.5375. [DOI] [PubMed] [Google Scholar]
  16. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77–92. doi: 10.1016/s0022-1759(98)00204-x. [DOI] [PubMed] [Google Scholar]
  17. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331–341. doi: 10.1016/j.immuni.2009.08.001. [DOI] [PubMed] [Google Scholar]
  18. Guermonprez P, Valladeau J, Zitvogel L, Théry CS, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621–667. doi: 10.1146/annurev.immunol.20.100301.064828. [DOI] [PubMed] [Google Scholar]
  19. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokiens and the expanding diversity of effector T cell leneages. Annu Rev Immunol. 2007;25:821–852. doi: 10.1146/annurev.immunol.25.022106.141557. [DOI] [PubMed] [Google Scholar]
  20. Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PloS One. 2011;19:e18909. doi: 10.1371/journal.pone.0018909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Francesco F, Romagnani S. Do studies in humans better depict Th17 cells. Blood. 2009;114:2213–2219. doi: 10.1182/blood-2009-03-209189. [DOI] [PubMed] [Google Scholar]
  22. Gao H, Ward PA. STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opin Ther Targets. 2007;11:869–880. doi: 10.1517/14728222.11.7.869. [DOI] [PubMed] [Google Scholar]
  23. Scott MJ, Godshall CJ, Cheadle WG. STATs, cytokines, and sepsis. Clin Diagn Lab Immunol. 2002;9:1153–1159. doi: 10.1128/CDLI.9.6.1153-1159.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal. 2009;7:1–32. doi: 10.1621/nrs.07003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. STAT3 dimerization regulated by reversible actylation of a single lysine residue. Science. 2005;307:269–273. doi: 10.1126/science.1105166. [DOI] [PubMed] [Google Scholar]
  26. Ohbayashi N, Ikeda O, Taira N, Yamamoto Y, Muromoto R, Sekine Y, et al. LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol Pharm Bull-4. 2007;30:1860. doi: 10.1248/bpb.30.1860. [DOI] [PubMed] [Google Scholar]
  27. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 2011;32:232–239. doi: 10.1016/j.it.2011.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal. 2011;23:1069–1075. doi: 10.1016/j.cellsig.2010.11.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol. 2007;8:247–256. doi: 10.1038/ni1439. [DOI] [PubMed] [Google Scholar]

Articles from Experimental & Molecular Medicine are provided here courtesy of Korean Society for Biochemistry and Molecular Biology

RESOURCES